The role of c-Src in lung cancer, its metastasis and anti-cancer therapy Editorial Cancer
More details
Hide details
Pneumonology Clinic, General Hospital of Serres
Corresponding author
Antonis Antoniadis   

Pneumonology Clinic General Hospital of Serres
Pneumon 2011;24(2):131–135
Yilmaz M, Christofori G, Lehembre F. Distinct mechanisms of tumor invasion and metastasis. Trends in Molecular Medicine, 2007; Vol. 13, No 12.
Guo G, Giancotti FG. Integrin signaling during tumor progression. Nat Rev Mol Cell Biol, 2004;5:816-826.
Tzouvelekis A, Karameris A, Bouros D. Telomeres, telomerase and immortality: A common link between lung cancer and pulmonary fibrosis. Pneumon, 2007;20:312-317.
Papalimneou V, Charalambopoulos C. Adhesion molecules and lung cancer. Pneumon, 2001;14:109-117.
Kumar CC. Signaling by integrin receptors. Oncogene, 1998;17:1365-1373.
Mitra SK, Schlaepfer D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Current opinion in Cell Biology, 2006;18:516-523.
Thomas SM, Brugges JS. Cellular functions regulated by Src family kinases. Ann Rev Cell Dev Biol, 1997;2:467-475.
Courtneidge SA. Role of Src in signal transduction pathways. Biochemical Society Transactions, 2002; Vol. 30, part 2.
Tatosyan AG, Mizenina OA. Kinases of the Src family: Structure and functions. Biochemistry, 1999;65:49-58.
Bjorge JD, Jakymiw A, Fujita JD. Selected glimpses into the activation and function of Src kinase. Oncogene 2000;19:5620-5635.
Lowell CA, Soriano P. Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Genes Dev, 1996;10:1845-1857.
Irby BR, Yeatman JT. Role of Src expression and activation in human cancer. Oncogene 2000;19:5636-5642.
Carney DN, Gazdar AF, Bepler G, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res, 1985;45:2913-23.
Mazurenko NN, Kogan AE, Zborovskaya BI, Kisseljov LF. Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J. Cancer, 1992;Vol. 28, No 2/3:372-377.
Masaki T, Igarashi K, Tokuda M, et al. pp60c-src activation in lung adenocarcinoma. European Journal of Cancer, 2003;39: 1447 1455 Inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol, 2010;28:1387-1394.
Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4:470-80.
Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene, 2004;23:7928-7946.
Cance WG, Harris JE, Iacocca MV, et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res, 2000;6:2417-2423.
Meng XN, Jin Y, Yu Y, et al. Characterization of fibronectinmediated FAK signaling pathways in lung cancer cell migration and invasion. British journal of cancer, 2009;101:327-334.
Byers LA, Sen B, Saigal B, et al. Reciprocal regulation of cSrc and STAT3 in non-small cell lung cancer. Clin Cancer Res 2009;15:6852-61. Epub 2009 Oct 27.
Giaccone G, Zucali PA. Src as a potential therapeutic target in non-small-cell lung cancer. Annals of Oncology, 2008;19:1219- 1223.
Song L, Morris M, Bagui T, Lee Y F, Jove R, Haura BE. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res, 2006; 66:(11).
Kim JI, Lakshmikanthan V, Frilot N, Daaka Y. Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome. Mol Cancer Res 2010;8:569-77. Epub 2010 Mar 30. PubMed PMID: 20353998; PubMed Central PMCID: PMC2855782.
Lee D, Gautschi O. Clinical development of Src tyrosine kinase inhibitors in lung cancer. Clinical lung cancer, 2006;7:6:381-384.
Rothschild SI, Gautschi O, Haura EB, Johnson FM. Src inhibitors in lung cancer: current status and future directions. Clin Lung Cancer 2010;11(4):238-42. Review. Pub Med PMID: 20630825.
Aleshin A, Finn SR. Src: a century of scince brought to the clinic, 2010;18:8:599-607.
Tsai YM, Yang CJ, Hsu YL, et al. Glabridin inhibits migration, invasion, and angiogenesis of human non-small cell lung cancer A549 cells by inhibiting the FAK/Rho signaling pathway. Integr Cancer Ther, 2010; 1-9 (in press).
Zhang J, Kalyankrishna S, Wislez M, et al. SRC-family kinases are activated in non–small cell lung cancer and promote the survival of epidermal growth factor receptor–dependent cell lines. Am J Pathol, 2007;170:366–376.
Haura EB, Tanvetanyon T, Chiapori A. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol, 2010; 28: 1387-1394.
Johnson FM, Tang X, Tran H, et al. Phase II study of dasatinib in non-small lung cancer (NSCLC). J Clin Oncol, 2009.